3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
4
Lymphoma, Non-Hodgkin
2
Recurrence
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
R-CHOP protocol
×
90 days
×
Clear all
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled